Biocon has received its board’s approval to transfer its Biosimilars business by way of a slump sale as ‘going concern’ to Biocon Biologics India, a step down wholly owned subsidiary of the Company, subject to consent of the shareholders of the Company and obtaining all requisite regulatory / statutory approvals.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.